Collegium Pharmaceutical Files 8-K Report

Ticker: COLL · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1267565

Collegium Pharmaceutical, Inc 8-K Filing Summary
FieldDetail
CompanyCollegium Pharmaceutical, Inc (COLL)
Form Type8-K
Filed DateJan 8, 2025
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, disclosure

TL;DR

Collegium Pharma filed an 8-K, mostly standard financial disclosures.

AI Summary

On January 8, 2025, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Collegium Pharmaceutical is providing updated financial information and disclosures to the SEC, which is standard practice for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

  • COLLEGIUM PHARMACEUTICAL, INC. (company) — Registrant
  • 0001104659-25-001873 (filing_id) — Accession Number
  • January 8, 2025 (date) — Date of Report
  • 100 Technology Center Drive Suite 300 Stoughton , MA 02072 (address) — Principal executive offices
  • 781-713-3699 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report financial statements and exhibits, along with a Regulation FD Disclosure.

What is the exact date of the earliest event reported?

The date of the earliest event reported is January 8, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 100 Technology Center Drive Suite 300 Stoughton, MA 02072.

What is Collegium Pharmaceutical, Inc.'s telephone number?

Collegium Pharmaceutical, Inc.'s telephone number is (781) 713-3699.

What is the company's state of incorporation?

The company's state of incorporation is Virginia.

Filing Stats: 1,142 words · 5 min read · ~4 pages · Grade level 14 · Accepted 2025-01-08 08:05:40

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2025, Collegium Pharmaceutical, Inc. (the "Company") issued a press release announcing full-year revenue, adjusted operating expense and adjusted EBITDA guidance for 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K. In addition, on January 8, 2025, the Company posted a corporate presentation to its website that representatives of the Company may use from time to time in presentations or discussions with investors, analysts or other parties. A copy of the presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K. To the extent that the information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished herewith, are not descriptions of historical facts regarding the Company, they are forward-looking Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished herewith, include, among others, statements related to the Company's full-year 2025 financial guidance, including projected product revenue, adjusted operating expenses and adjusted EBITDA, current and future market opportunities for its products and the Company's assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated January 8, 2025. 99.2 Investor Presentation, dated January 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2025 Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Name: Colleen Tupper Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.